Evidence map›Paper›PMID 32054656›Full record

ArticleHaematologica2021

Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphoma.

Shingo Nakahata, Chilmi Syahrul, Ayako Nakatake, Kuniyo Sakamoto, Maki Yoshihama, Ichiro Nishikata, Yoshinori Ukai, Tadashi Matsuura, Takuro Kameda, Kotaro Shide and 18 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Virus, Exosome, and MicroRNA: New Insights into Autophagy.Advances in experimental medicine and biology · 2022
    Article
  6. Review
  7. The Role of Cell Adhesion Molecule 1 (CADM1) in Cutaneous Malignancies.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 12 institutions in 1 country.

Shingo NakahataDepartment of Medical Sciences, University of Miyazaki, Miyazaki, Japan.
Chilmi SyahrulDepartment of Medical Sciences, University of Miyazaki, Miyazaki, Japan.
Ayako NakatakeDepartment of Medical Sciences, University of Miyazaki, Miyazaki, Japan.
Kuniyo SakamotoDepartment of Medical Sciences, University of Miyazaki, Miyazaki, Japan.
Maki YoshihamaDepartment of Medical Sciences, University of Miyazaki, Miyazaki, Japan.
Ichiro NishikataDepartment of Medical Sciences, University of Miyazaki, Miyazaki, Japan.
Yoshinori UkaiPerseus Proteomics Inc., Tokyo, Japan.
Tadashi MatsuuraPerseus Proteomics Inc., Tokyo, Japan.
Takuro KamedaDepartment of Internal Medicine, University of Miyazaki, Miyazaki, Japan.
Kotaro ShideDepartment of Internal Medicine, University of Miyazaki, Miyazaki, Japan.
Yoko KubukiDepartment of Internal Medicine, University of Miyazaki, Miyazaki, Japan.
Tomonori HidakaDepartment of Internal Medicine, University of Miyazaki, Miyazaki, Japan.
Akira KitanakaDepartment of Laboratory Medicine, Kawasaki Medical School, Okayama, Japan.
Akihiko ItoDepartment of Pathology, Kindai University School of Medicine, Osaka, Japan.
Shigeki TakemotoNational Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
Nobuaki NakanoDepartment of Hematology, Imamura General Hospital, Kagoshima, Japan.
Masumichi SaitoNational Institute of Infectious Diseases, Tokyo, Japan.
Masako IwanagaDept of Frontier Life Science, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Yasuko SagaraJapanese Red Cross Kyushu Block Blood Center, Fukuoka, Japan.
Kosuke MochidaDepartment of Dermatology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Masahiro AmanoDepartment of Dermatology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Kouichi MaedaInternal Medicine, National Hospital Organization Miyakonojo Medical Center, Miyazaki, Japan.
Eisaburo SueokaDepartment of Laboratory Medicine, Saga University Hospital, Saga, Japan.
Akihiko OkayamaDept. of Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan.
Atae UtsunomiyaDepartment of Hematology, Imamura General Hospital, Kagoshima, Japan.
Kazuya ShimodaDepartment of Internal Medicine, University of Miyazaki, Miyazaki, Japan.
Toshiki WatanabeDepartment of Computational Biology and Medical Sciences, University of Tokyo, Japan.
Kazuhiro MorishitaDepartment of Medical Sciences, University of Miyazaki, Miyazaki, Japan.
University of Miyazaki · JPEcogenomics (Japan) · JPImamura Hospital · JPJapanese Red Cross Fukuoka Hospital · JPKawasaki Medical School · JPKindai University · JPKumamoto Medical Center · JPNagasaki University · JPNational Hospital Organization Miyazaki Higashi Hospital · JPNational Institute of Infectious Diseases · JPSaga University · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adult T-cell leukemia/leukemia (ATLL) is an aggressive peripheral T-cell malignancy, caused by infection with the human T-cell leukemia virus type 1 (HTLV-1). We have recently shown that cell adhesion molecule 1 (CADM1), a member of the immunoglobulin superfamily, is specifically and consistently overexpressed in ATLL cells, and functions as a novel cell surface marker. In this study, we first show that a soluble form of CADM1 (sCADM1) is secreted from ATLL cells by mainly alternative splicing. After developing the Alpha linked immunosorbent assay (AlphaLISA) for sCADM1, we showed that plasma sCADM1 concentrations gradually increased during disease progression from indolent to aggressive ATLL. Although other known biomarkers of tumor burden such as soluble interleukin-2 receptor α (sIL-2Rα) also increased with sCADM1 during ATLL progression, multivariate statistical analysis of biomarkers revealed that only plasma sCADM1 was selected as a specific biomarker for aggressive ATLL, suggesting that plasma sCADM1 may be a potential risk factor for aggressive ATLL. In addition, plasma sCADM1 is a useful marker for monitoring response to chemotherapy as well as for predicting relapse of ATLL. Furthermore, the change in sCADM1 concentration between indolent and aggressive type ATLL was more prominent than the change in the percentage of CD4+CADM1+ ATLL cells. As plasma sCADM1 values fell within normal ranges in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients with higher levels of serum sIL-2Rα, a measurement of sCADM1 may become a useful tool to discriminate between ATLL and other inflammatory diseases, including HAM/TSP.

Indexed as

Human T-lymphotropic virus 1Leukemia-Lymphoma, Adult T-CellLymphomaAdultBiomarkersCell Adhesion Molecule-1HumansBiomarkersCADM1 protein, humanCell Adhesion Molecule-1

Identifiers

PMID32054656
PMCPMC7849584
OpenAlexW3006295304

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.